Curcumin, a polyphenol compound that belongs to a class
of molecules
known as curcuminoids, may interact with various biological macromolecules
in the body, including proteins, nucleic acids, and lipids. Curcumin-based
fixed-dose combination (FDC) products enhance curcumin stability and
bioavailability for better clinical use in cholesterol management.
Preclinical studies on curcumin and cholesterol are mostly positive.
Obstacles are the variable composition of the many different curcumin-based
FDC products, the lack of standards, and the limitation of the randomized
controlled trials (RCTs) conducted for specific products. Once these
downfalls have been addressed, curcumin-based FDC products have great
potential for cholesterol management. They can supplement the uptake
of statins, reducing their dosage for the same controlling effects
or even replacing them.